Labiotech.eu

News and Trends 9 Sep 2016

How to get Antibiotic free Bioproduction in Biotech with Delphi Genetics

After Vienna, it’s time to jump in the middle of the Paris-Amsterdam-Frankfurt triangle in the BioPark of Brussels South in Belgium. We will meet a company who can answer the problem of antibiotic use in the bacterial strains selection whilst, at the same time, increasing bioproduction yield. Our Biotech of the week, Delphi Genetics. City: Gosselies […]

September 9, 2016 - 4 minutesmins - By Jerome Topsent

News and Trends 9 Sep 2016

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

A German biotech has surfaced with a promising new drug for traumatic brain injury: vasopharm’s Nitrous Oxide Synthase inhibitor is starting Phase III. In news from the novel and obscure, someone has taken an interest in Nitrous Oxide Synthase (NOS). That someone is vasopharm GmbH, a small German biopharmaceutical company interested in cerebrovascular diseases. The company has […]

September 9, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 8 Sep 2016

Allergan seizes visionary Optogenetic Therapy from US Startup

Allergan is diving into gene therapy with the acquisition of RetroSense Therapeutic’s new early clinical candidate, RST-001. The drug aims to remedy Retinitis Pigmentosa, which affects between 13 and 44 in 100k people worldwide. Allergan has just acquired RetroSense Therapeutics as part of their ongoing effort in eye care. The core of the deal was […]

September 8, 2016 - 2 minutesmins - By Evelyn Warner

In Depth 8 Sep 2016

Stem Cell Tourism makes Big Promises but may End your Life…

Desperate patients are ready to do everything to access to new treatments and Google searches can help them find medicines in the early stages of development rather than those with proper authorization. They latch on to this false hope and travel to search for treatments, sometimes with deadly consequences. When you are chatting about health […]

September 8, 2016 - 5 minutesmins - By Timothé Cynober

News and Trends 7 Sep 2016

Building Life from DNA Legos, a Review of Synthetic Biology

It sounds like a lot of fun, but DNA legos are serious: they represent the core concept of synthetic biology, a field with the potential to solve major issues in public health, society and the environment. Here’s a survey of this exciting new area of development. Major thanks to Eshna Gogia at Helixworks for letting us use her article as a source! […]

September 7, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 7 Sep 2016

Promising Boston-based CRISPR Startup hits up Horizon to fix Gene Misregulation

An American outfit from Third Rock Ventures, Fulcrum Therapeutics, has made a deal with Horizon to access its catalogue of genetic anomalies. The collaboration will target diseases arising from gene misregulation. Horizon Discovery has announced a collaboration with Fulcrum Therapeutics, launched earlier this year by Third Rock Ventures, to target diseases caused by gene regulation malfunction. Fulcrum […]

September 7, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 6 Sep 2016

Denmark: The ‘Best CEO of the World’ to retire at Year’s End

The CEO of Novo Nordisk, who was named ‘Best CEO in the World’ by the Harvard Business Review in October 2015, will not have a chance to dominate the ranking again next year. He will retire by the end of the year (and have some well-deserved holidays). Lars Sorensen, or rather, Sørensen, joined the world-leading producer […]

September 6, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 6 Sep 2016

“This Phase I could Pioneer Needle-free Vaccines”, DBV’s CEO

How annoying are needle vaccinations? Very … But the French billion-euro Biotech DBV Technologies wants to bring a paradigm shift via its Anti-allergy Patch platform! I got to chat with the founder & CEO, Pierre-Henri Benhamou, for more insights. DBV’s success continues to amaze me. It’s not only close to solving the global peanut and […]

September 6, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 6 Sep 2016

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Rigontec is taking a totally new RNA-based approach to immuno-oncology via the RIG-I receptors. The company extended its Series A fundraising to a third round, and some of the top European VC’s doubled its cash pile to almost €30M. Since launching in early 2014, Munich-based Rigontec has broken with traditional immuno-oncology and pioneered a new RNA avenue […]

September 6, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

Amgen ties up loose ends after Largest Biotech Acquisition in Germany

Before Amgen, the largest biotech company in the world, acquired Micromet in one of the splashiest biotech deals in Europe, Micromet licensed its BiTE technology to Boehringer Ingelheim. Amgen is now taking over the development of BI’s Multiple Myeloma therapy to consolidate its hold on the bispecific antibodies. Boehringer Ingelheim has handed Amgen the keys to its Bispecific T cell […]

September 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

Could Artificial Enzymes be the Future of Synthetic Chemistry?

As synthetic organic chemistry struggles to reinvent itself, the field is shifting its focus to emulating and engineering enzymes. A team of researchers in Basel has developed an artificial metalloenzyme with unique functionality that can be activated in a cell. Since the first example was published in 2015, artificial enzymes have been a hot topic […]

September 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

NanoTemper: the Game-changer for Drug Development Technologies

“Getting better drugs faster” is what biochemist Dr. Stefan Duhr and biophysicist Dr. Philipp Baaske envisioned when they started building NanoTemper Technologies. Established in 2008 in Munich, NanoTemper Technologies provides innovative solutions to help develop biological products. For the past 8 years, many great products have been launched like the Monolith instruments series – providing MicroScale Thermophoresis (MST), an easy, fast […]

September 5, 2016 - 4 minutesmins - By Jerome Topsent

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

How to get Antibiotic free Bioproduction in Biotech with Delphi Genetics

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

Allergan seizes visionary Optogenetic Therapy from US Startup

Stem Cell Tourism makes Big Promises but may End your Life…

Building Life from DNA Legos, a Review of Synthetic Biology

Promising Boston-based CRISPR Startup hits up Horizon to fix Gene Misregulation

Denmark: The ‘Best CEO of the World’ to retire at Year’s End

“This Phase I could Pioneer Needle-free Vaccines”, DBV’s CEO

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Amgen ties up loose ends after Largest Biotech Acquisition in Germany

Could Artificial Enzymes be the Future of Synthetic Chemistry?

NanoTemper: the Game-changer for Drug Development Technologies

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!